>





A heptapeptide analog of ACTH(4-10) with neuroprotective and BDNF-modulating activity. Investigated as a research tool for cognitive pharmacology.
Semax is a synthetic heptapeptide analog of ACTH(4-7) extended by a Pro-Gly-Pro tripeptide. Unlike full ACTH, it does not stimulate corticosteroid release; instead, it modulates BDNF expression, NGF/TrkA signaling, and dopaminergic/serotonergic activity in the CNS.
Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.
BDNF/NGF expression assays in cortical neurons, behavioral pharmacology in rodent learning/memory paradigms, and TrkA/TrkB signaling investigations.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
| Parameter | Value |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular formula | C₃₉H₅₄N₁₀O₁₀S |
| Molecular weight | 854.97 g/mol |
| CAS number | 80714-61-0 |
| Length | 7 residues |
| Test | Specification |
|---|---|
| HPLC purity | ≥ 99.0% (lot LM-2660: 99.22%) |
| Mass confirmation | ESI-MS within 0.5 Da |
| Net peptide content | ≥ 80% by AAA |
| Endotoxin | < 0.5 EU/mg (LAL) |
| Bioburden | < 10 CFU/g |
| Residual TFA | < 1.0% |
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.
| Method | Result |
|---|---|
| RP-HPLC at 220 nm | 99.22% main peak |
| ESI-MS (positive) | 855.0 Da (theor. 854.97) |
| Amino acid analysis | 82.1% net peptide |
| LAL endotoxin | < 0.05 EU/mg |
| Karl Fischer (water) | 2.8% w/w |
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Levitskaya NG et al. Effects of semax and its C-terminal fragment Pro-Gly-Pro on the behavior of white rats. Neurosci Behav Physiol. 2002;32(4):355–360.
Dolotov OV et al. Semax, an analog of ACTH(4-10), and its des-glycine analog: synthesis, biological activity. J Mol Neurosci. 2006;28(2):133–141.
Andreeva LA et al. Synthetic heptapeptide Semax. Russ J Bioorg Chem. 2010;36(4):457–467.
Semax reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-SEMAX-30, Lot 26-A031.
Semax is a synthetic ACTH 4-7 analog, classified within the neurotrophic signaling pathway. Structurally it is a Met-Glu-His-Phe-Pro-Gly-Pro heptapeptide. Semax is a synthetic heptapeptide analog of ACTH(4-10) developed by Russian neuroscientists. Levitskaya et al. (2002) reviewed its nootropic and neuroprotective effects in animal models.
In an in-vitro setting, Semax interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.
Semax arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
For laboratory research only. Semax is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.